Mergers & Acquisitions Mergers & Acquisitions

Comment: Thermo Fisher-Qiagen antitrust review likely to focus on sample preparation

By Flavia Fortes
  • 13 Mar 2020 15:22
  • 24 Mar 2020 09:32
The antitrust review of Thermo Fisher Scientific's proposed acquisition of genetic testing company Qiagen is likely to focus on the companies’ overlaps in sample preparation for next-generation sequencing, or NGS.
Medical technology company Thermo Fisher announced on March 3 its plans to buy Netherlands-based holding company Qiagen for $11.5 billion.

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers

Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

Latest News